053950.KQ Kyung Nam Pharm Co Ltd
- Market cap
- -
- P/E
- -
- P/B
- 0.25x
- ROE
- -7.3%
- Dividend yield
- -
- Fundamental score
- 0.7/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 053950.KQ undervalued?
Graham numberThe Graham number of Kyung Nam Pharm Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kyung Nam Pharm Co Ltd fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-7.3%), below 10%.
ROA 0/1
Return on assets (-5.3%) is below the industry median (3.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-189.4%) is below the industry median (6.6%).
Revenue Growth 0/2
Revenue shrank 1.8% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 1/2
Cash covers 1.2 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.3x) is below the industry median (0.8x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Kyung Nam Pharm Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kyung Nam Pharm Co Ltd
Kyung Nam Pharm Co.,Ltd. manufactures pharmaceuticals. The company offers over-the-counter products, including antipyretics, analgesics, and antiphlogistics; medications for skin diseases and athlete's foot; pain relief patches/creams, antitussives, mucolytic agents, and expectorants; gastro protective agents/digestives; periodontal/gum disease drugs; medications for liver diseases; ear and nose solutions; nutritious tonics; circulatory drugs; and vitamins and minerals produ…
Full company profileKyung Nam Pharm Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kyung Nam Pharm Co Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2010 | 2016 | 2017 | 2018 | 2019 | 2020 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 52.4B | 39.8B | 40.2B | 41.4B | 44.8B | 70.9B | 59.0B | 59.3B | 60.8B | 55.9B | 67.9B |
| Gross Profit | - | 17.4B | 17.1B | 16.7B | 16.8B | 28.5B | 16.4B | 19.3B | 17.2B | 15.1B | 19.6B |
| Operating Income | 656M | 2.21B | 3.29B | -2.27B | -4.94B | 2.18B | -3.39B | -3.59B | -243M | -1.73B | 331M |
| EBITDA | - | - | - | - | - | - | -3.48B | -4.08B | 1.24B | -5.91B | -5.20B |
| Net Income | - | 130M | -3.48B | 3.72B | -4.55B | -5.49B | -7.83B | -21.0B | 10.1B | -9.01B | -7.65B |
| EPS | - | - | - | - | - | - | -819 | -2,067 | 578 | -516 | -439 |
| Balance Sheet | |||||||||||
| Total Assets | 89.2B | 45.2B | - | 53.2B | 74.5B | 127B | 138B | 167B | 167B | 156B | 143B |
| Total Liabilities | 67.2B | 28.4B | - | 24.2B | 13.3B | 69.3B | 44.5B | 76.8B | 51.4B | 47.3B | 25.7B |
| Shareholders' Equity | 16.2B | 16.8B | - | 28.9B | 61.2B | 57.4B | 93.8B | 79.4B | 115B | 108B | 105B |
| Cash & Short-term Investments | 11.2B | 5.27B | - | 8.42B | 23.9B | 27.5B | 43.0B | 26.0B | 50.8B | 6.25B | 18.4B |
| Total Debt | - | 5.00B | - | - | 390M | 27.7B | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 483M | 4.89B | 1.72B | -1.75B | -6.43B | 2.62B | 71.6M | 693M | 1.84B | -1.68B | -5.52B |
| Capital Expenditure | 10.9B | 1.11B | 1.05B | 527M | 1.32B | 45.6B | 2.92B | 4.18B | 1.67B | 1.26B | 9.23B |
| Free Cash Flow | - | - | - | - | - | - | -2.85B | -3.48B | 172M | -2.94B | -14.7B |
| Ratios | |||||||||||
| ROE | - | 0.8% | - | 12.9% | -7.4% | -9.6% | -8.3% | -26.5% | 8.7% | -8.3% | -7.3% |
| ROA | - | 0.3% | - | 7.0% | -6.1% | -4.3% | -5.7% | -12.6% | 6.0% | -5.8% | -5.3% |
| Net Profit Margin | - | 0.3% | -8.7% | 9.0% | -10.1% | -7.7% | -13.3% | -35.4% | 16.6% | -16.1% | -11.3% |
| Debt to Equity | - | 0.30x | - | - | 0.01x | 0.48x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Kyung Nam Pharm Co Ltd dividends
Kyung Nam Pharm Co Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1:5 on May 7, 2026.
Who owns Kyung Nam Pharm Co Ltd
- Insiders 24.06%
- Institutions 0.09%
- Public & others 75.85%
- Free float 11.9M
Kyung Nam Pharm Co Ltd company profile
- Company name
- Kyung Nam Pharm Co Ltd
- Ticker
- 053950.KQ
- ISIN
- KR7053950002
- Exchange
- KOSDAQ
- Sector
- -
- Industry
- Pharmaceuticals
- Employees
- 247
- Fiscal year end
- December
- Address
- 79 Guryong-ro 4 nam-gi, Uiryeong, South Korea, 636-800
- Phone
- 82 2 3490 5157
- Website
- kyungnampharm.co.kr
About Kyung Nam Pharm Co Ltd
Kyung Nam Pharm Co.,Ltd. manufactures pharmaceuticals. The company offers over-the-counter products, including antipyretics, analgesics, and antiphlogistics; medications for skin diseases and athlete's foot; pain relief patches/creams, antitussives, mucolytic agents, and expectorants; gastro protective agents/digestives; periodontal/gum disease drugs; medications for liver diseases; ear and nose solutions; nutritious tonics; circulatory drugs; and vitamins and minerals products. It also provides prescription-only medicines, such as pure kin solutions, plagensia inj., arobin inj., and galonic inj.; quasi drugs, such as vitamins and other drugs; health functional food products, including intestine health, weight loss, stress relieve, and vitamins and minerals; as well as other food products. Kyung Nam Pharm Co.,Ltd. was formerly known as HS Bio Pharm Co., Ltd. and changed its name to Kyung Nam Pharm Co.,Ltd. in May, 2010. Kyung Nam Pharm Co.,Ltd. was founded in 1957 and is headquartered in Uiryeong, South Korea with an additional office in Seoul, South Korea.
Kyung Nam Pharm Co Ltd management
2- Ms. Eun HoeSr. Managing Director · born 1960
- Mr. Oh Chang HwanChief Exec. Officer